Title: AMPLITUDE (A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- Principal Investigator: Dr. Eric Knoche
- Study Coordinator: Carley Browning
The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) provides superior efficacy in improving radiographic progression-free survival (rPFS)
Co-Investigator, Dr. Martin Schoen, was recognized for his work on the project on the ORD website.
This study is administered by VREF and funded by Janseen.
This study is currently enrolling patients. To learn more about AMPLITUDE and how you can join contact our research office at (314) 289-7690.